"The Food and Drug Administration (FDA) Center for Biologics Evaluation and ..."

Azadeh Shoaibi et al. (2020)

> Home

Details and statistics

DOI: —

access: closed

type: Conference or Workshop Paper

metadata version: 2024-04-17

- view
  - electronic edition @ amia.org (archived)
- export record
  dblp key:
  - conf/amia/ShoaibiWRMH20
- ask others
- share record
  persistent URL:
  - https://dblp.org/rec/conf/amia/ShoaibiWRMH20
Azadeh Shoaibi, Hui-Lee Wong, Christian Reich, Keran Moll, Tina Hernandez-Boussard:
The Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative: How Informatics Can Assist the Secondary Use of Electronic Health Records to Inform Regulatory Decisions. AMIA 2020

manage site settings

To protect your privacy, all features that rely on external API calls from your browser are turned off by default. You need to opt-in for them to become active. All settings here will be stored as cookies with your web browser. For more information see our F.A.Q.